Ifp Advisors, Inc Clovis Oncology, Inc. Transaction History

Ifp Advisors, Inc

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 07, 2023	BUY	$0.05 - $1.3 $2 - $65	50 Added 0.5%	10,050 $479,000
Q3 2022 Nov 08, 2022	BUY	$1.05 - $2.85 $10,500 - $28,500	10,000 New	10,000 $477,000
Q3 2021 Oct 06, 2021	SELL	$4.06 - $5.8 $1,420 - $2,030	-350 Closed	0 $0
Q1 2021 Apr 30, 2021	BUY	$4.81 - $10.34 $1,683 - $3,619	350 New	350 $2,000
Q4 2020 Jan 25, 2021	BUY	$4.13 - $6.41 $0 - $0	0 New	0 $0
Q3 2020 Oct 29, 2020	BUY	$4.82 - $7.72 $0 - $0	0 New	0 $0
Q2 2020 Aug 05, 2020	BUY	$5.69 - $9.69 $0 - $0	0 New	0 $0
Q1 2020 May 12, 2020	BUY	$3.77 - $11.0 $0 - $0	0 New	0 $0
Q4 2019 Jan 17, 2020	SELL	$3.0 - $16.43 $570 - $3,121	-190 Closed	0 $0
Q3 2019 Nov 07, 2019	BUY	$3.93 - $15.35 $746 - $2,916	190 New	190 $1,000
Q1 2019 May 15, 2019	SELL	$17.66 - $30.28 $4,415 - $7,570	-250 Closed	0 $0
Q4 2018 Jan 23, 2019	BUY	$11.63 - $32.67 $2,907 - $8,167	250 New	250 $4,000
Q2 2018 Aug 07, 2018	SELL	$42.06 - $62.4 $16,824 - $24,960	-400 Closed	0 $0
Q1 2018 Jun 03, 2019	SELL	$50.12 - $67.72 $5,012 - $6,772	-100 Reduced 20.0%	400 $27,000
Q1 2018 May 09, 2018	BUY	$50.12 - $67.72 $5,012 - $6,772	100 Added 25.0%	500 $0
Q4 2017 Jan 24, 2018	SELL	$57.69 - $84.58 $49,036 - $71,893	-850 Reduced 68.0%	400 $0
Q3 2017 Oct 30, 2017	SELL	$67.17 - $84.81 $10,411 - $13,145	-155 Reduced 11.03%	1,250 $103,000
Q2 2017 Jun 03, 2019	SELL	N/A	-1,705 Reduced 54.82%	1,405 $132,000
Q1 2017 Jun 03, 2019	SELL	N/A	-965 Reduced 23.68%	3,110 $198,000
Q4 2016 Jun 03, 2019	SELL	N/A	-1,925 Reduced 32.08%	4,075 $181,000
Q2 2016 Jun 03, 2019	BUY	N/A	6,000	6,000 $82,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ifp Advisors, Inc with notifications on news.